Mirum Pharmaceuticals, Inc. - MIRM STOCK NEWS

Mirum Pharmaceuticals (NASDAQ: MIRM) will host an investor call on June 17, 2024, at 8:30 a.m. ET to present interim results from two Phase 2b studies: the Volixibat VANTAGE study for primary biliary cholangitis (PBC) and the Volixibat VISTAS study for primary sclerosing cholangitis (PSC). Dial-in options are available, and a webcast will be accessible on Mirum's website. The replay of the call will be available for 30 days.

Mirum Pharmaceuticals (NASDAQ: MIRM) has announced the grant of inducement awards to 14 new employees under its 2020 Inducement Plan. On June 10, 2024, the Compensation Committee of Mirum’s Board of Directors approved stock options for 56,600 shares and 28,300 restricted stock units (RSUs). The stock options have an exercise price of $25.55 per share and will vest over four years, with 25% vesting after one year and the remainder vesting monthly over the next three years. The RSUs will vest over three years, with 33% vesting annually. These awards are in accordance with Nasdaq Listing Rule 5635(c)(4).

Mirum Pharmaceuticals presented data at the EASL Congress showing long-term benefits of LIVMARLI (maralixibat) in treating Alagille syndrome (ALGS) and Progressive Familial Intrahepatic Cholestasis (PFIC). The MERGE study demonstrated sustained clinical benefits for ALGS patients over seven years, including reductions in pruritus and serum bile acids, and improvements in height.

The MARCH/MARCH-ON trials indicated statistically significant growth improvements in PFIC patients over 82 weeks, with better height and weight z-scores. Another analysis from these trials showed that reductions in serum bile acids correlated with improved liver health markers like bilirubin, suggesting potential disease-modifying effects of LIVMARLI.

Mirum Pharmaceuticals (Nasdaq: MIRM) announced its participation in the Goldman Sachs 45th Annual Global Healthcare Conference in Miami on June 12th at 10:00 AM EDT.

The company, known for developing therapies for rare and orphan diseases, will provide a presentation accessible via the Investors and Media section on Mirum's corporate website.

For more details, investors can visit the company's site for webcast links and additional information.

Mirum Pharmaceuticals has received a positive opinion from the European Committee for Medicinal Products for Human Use (CHMP) for LIVMARLI® (maralixibat) oral solution for treating Progressive Familial Intrahepatic Cholestasis (PFIC) in patients aged three months and older. This decision is based on the Phase 3 MARCH study, which showed a highly significant reduction in pruritus severity (p<0.0001) compared to placebo across all PFIC types. Furthermore, the Committee for Orphan Medicinal Products (COMP) recommended maintaining the Orphan Drug Designation for LIVMARLI in PFIC. A final decision by the European Commission is expected in Q3 2024. Currently, LIVMARLI is approved for treating cholestatic pruritus in Alagille syndrome (ALGS) in Europe and the U.S., and for PFIC in U.S. patients aged five years and older. Mirum also plans to submit a supplemental new drug application (sNDA) to expand the label for younger PFIC patients in the U.S.

Mirum Pharmaceuticals announced the presentation of new long-term data from LIVMARLI studies at the upcoming EASL Annual Congress in Milan, Italy (June 5-8, 2024). The data highlights sustained clinical benefits of LIVMARLI for Alagille syndrome (ALGS) over seven years and improvements in liver markers and growth for Progressive Familial Intrahepatic Cholestasis (PFIC) patients. Key presentations include:

- THU-094: Clinical benefits of Maralixibat for ALGS patients through 7 years (MERGE Study).

- THU-129: Maralixibat improves growth in PFIC patients (MARCH/MARCH-ON Trials).

- THU-158: Serum bile acid levels and liver health improvements in PFIC children after Maralixibat treatment (MARCH/MARCH-ON Trials).

Additionally, a Mirum-sponsored symposium will discuss the role of IBAT inhibitors in adult hepatology and unmet needs in primary sclerosing cholangitis (PSC).

Mirum Pharmaceuticals presented data on their oral solution, LIVMARLI (maralixibat), at the 56th ESPGHAN Annual Meeting in Milan. Seven abstracts highlighted LIVMARLI's efficacy in treating Alagille syndrome (ALGS) and Progressive Familial Intrahepatic Cholestasis (PFIC). Key findings from the Phase 3 MARCH-ON PFIC study showed significant and sustained improvements in pruritus severity, serum bile acid levels, total bilirubin, and growth over two years. One-third of patients on LIVMARLI discontinued at least one antipruritic medication. These results underscore LIVMARLI's potential in improving liver health and reducing medication dependency in children with PFIC and ALGS.

Mirum Pharmaceuticals, Inc. announced the granting of inducement awards to new employees under the 2020 Inducement Plan. The grants consist of stock options and restricted stock units (RSUs) totaling 38,600 shares of common stock and 19,300 RSUs. The stock options have an exercise price of $24.76 per share, will vest over four years, and the RSUs will vest over three years. The awards were approved by the Compensation Committee of Mirum's Board of Directors as an inducement material for the new employees' employment.

Mirum Pharmaceuticals reported a strong first quarter in 2024, with total revenue of $69.2 million and on track to achieve full-year guidance of $310 to $320 million. The FDA approval of LIVMARLI for cholestatic pruritus in PFIC patients was achieved in March. The company maintains a cash balance of $302.8 million as of March 31, 2024, and has important interim analyses scheduled for June 2024. Mirum's commercial business is performing well, with continued demand growth and net sales increase.